Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...

New World Health Organisation (WHO) recommendations for the use of long-acting HIV prevention and treatment are a welcome boost in the global efforts to end ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

Lenacapavir-a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences-is now recommended by the World Health ...

Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...